- Home
- NERV vs BLRX Comparison
NERV vs BLRX Comparison
Compare NERV & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- BLRX
- Stock Information
- Founded
- NERV 2007
- BLRX 2003
- Country
- NERV United States
- BLRX Israel
- Employees
- NERV N/A
- BLRX N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- NERV Health Care
- BLRX Health Care
- Exchange
- NERV Nasdaq
- BLRX Nasdaq
- Market Cap
- NERV 10.7M
- BLRX 12.2M
- IPO Year
- NERV 2014
- BLRX 2011
- Fundamental
- Price
- NERV $1.61
- BLRX $3.10
- Analyst Decision
- NERV Hold
- BLRX Buy
- Analyst Count
- NERV 1
- BLRX 2
- Target Price
- NERV $5.00
- BLRX $26.00
- AVG Volume (30 Days)
- NERV 15.1K
- BLRX 26.4K
- Earning Date
- NERV 04-30-2025
- BLRX 05-27-2025
- Dividend Yield
- NERV N/A
- BLRX N/A
- EPS Growth
- NERV N/A
- BLRX N/A
- EPS
- NERV 0.19
- BLRX N/A
- Revenue
- NERV N/A
- BLRX $28,940,000.00
- Revenue This Year
- NERV N/A
- BLRX N/A
- Revenue Next Year
- NERV N/A
- BLRX N/A
- P/E Ratio
- NERV $8.95
- BLRX N/A
- Revenue Growth
- NERV N/A
- BLRX 502.92
- 52 Week Low
- NERV $1.42
- BLRX $2.85
- 52 Week High
- NERV $3.69
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- NERV 41.00
- BLRX 41.70
- Support Level
- NERV $1.54
- BLRX $3.01
- Resistance Level
- NERV $1.89
- BLRX $3.61
- Average True Range (ATR)
- NERV 0.11
- BLRX 0.22
- MACD
- NERV 0.00
- BLRX 0.02
- Stochastic Oscillator
- NERV 22.68
- BLRX 32.89
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.